- Home
- DNLI vs FOLD Comparison
DNLI vs FOLD Comparison
Compare DNLI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- FOLD
- Stock Information
- Founded
- DNLI 2013
- FOLD 2002
- Country
- DNLI United States
- FOLD United States
- Employees
- DNLI N/A
- FOLD N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- DNLI Health Care
- FOLD Health Care
- Exchange
- DNLI Nasdaq
- FOLD Nasdaq
- Market Cap
- DNLI 2.3B
- FOLD 2.5B
- IPO Year
- DNLI 2017
- FOLD 2007
- Fundamental
- Price
- DNLI $15.21
- FOLD $8.04
- Analyst Decision
- DNLI Strong Buy
- FOLD Strong Buy
- Analyst Count
- DNLI 15
- FOLD 9
- Target Price
- DNLI $33.50
- FOLD $26.44
- AVG Volume (30 Days)
- DNLI 2.0M
- FOLD 5.9M
- Earning Date
- DNLI 11-05-2025
- FOLD 11-05-2025
- Dividend Yield
- DNLI N/A
- FOLD N/A
- EPS Growth
- DNLI N/A
- FOLD N/A
- EPS
- DNLI N/A
- FOLD N/A
- Revenue
- DNLI N/A
- FOLD $571,160,000.00
- Revenue This Year
- DNLI N/A
- FOLD $21.04
- Revenue Next Year
- DNLI $95,463.19
- FOLD $21.34
- P/E Ratio
- DNLI N/A
- FOLD N/A
- Revenue Growth
- DNLI N/A
- FOLD 25.35
- 52 Week Low
- DNLI $10.57
- FOLD $5.51
- 52 Week High
- DNLI $33.33
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- DNLI 54.76
- FOLD 51.01
- Support Level
- DNLI $15.03
- FOLD $8.01
- Resistance Level
- DNLI $16.51
- FOLD $8.51
- Average True Range (ATR)
- DNLI 0.80
- FOLD 0.35
- MACD
- DNLI 0.11
- FOLD -0.04
- Stochastic Oscillator
- DNLI 61.42
- FOLD 39.44
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.